MTEX Mannatech
Nasdaq · Health Care · Medicinal Chemicals & Botanical Products · latest quarter in EDGAR: 2026-06-30
Mannatech (MTEX) is in ThetaGrade’s extended coverage. It does not have a House Rating; this is a fundamentals-only summary from SEC filings, compared with Health Care peers. Overall its fundamentals read Mixed (Growth: below average; Profitability: above average; Balance sheet: average). 86% of the method weight is backed by data.
Data as of .
Growth
Below average| Revenue growth (TTM, YoY) | Below average |
| EPS growth (TTM, YoY) | data gap |
Profitability
Above average| Operating margin (TTM) | Above average |
| Free-cash-flow margin (TTM) | Average |
Balance sheet
Average| Net debt / EBITDA | Above average |
| Current ratio | Bottom quintile |
| Interest coverage | Top quintile |
From the filings
- Operating profit (TTM)
- Revenue down year over year
- Net cash
- Free cash flow negative (TTM)
- Negative shareholder equity
Next earnings
Estimated window 2026-02-10 to 2027-08-12 (rough estimate; estimated from SEC 8-K Item 2.02 filing history (not company-confirmed)). Back-test max error 274 days (> 7).
Why no House Rating
- price under $10
- market cap under $1B
House Ratings, Weekly Picks and the CSP screen cover the Tier 1 universe only. Methodology
Get rating changes in the free Daily Brief
The market’s key events and signals, digested before the open.
- ✓ Pre-market Daily Brief: events, headlines, rating changes (2-min read)
- ✓ Sunday: Top 5 Weekly Picks, exit alerts, CSP put watchlist
- ✓ OPEX, FOMC, CPI and jobs-day reminders
Free. Want more? See Premium.
Educational summary from public SEC filings; not a House Rating and not financial advice. Sector: SIC 2833 (Medicinal Chemicals & Botanical Products). Source: SEC EDGAR filings. Data as of 2026-10-21.